331 related articles for article (PubMed ID: 26314196)
1. The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature.
Simonsen AH; Kuiperij B; El-Agnaf OM; Engelborghs S; Herukka SK; Parnetti L; Rektorova I; Vanmechelen E; Kapaki E; Verbeek M; Mollenhauer B
Biomark Med; 2016; 10(1):19-34. PubMed ID: 26314196
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
Ohrfelt A; Grognet P; Andreasen N; Wallin A; Vanmechelen E; Blennow K; Zetterberg H
Neurosci Lett; 2009 Feb; 450(3):332-5. PubMed ID: 19022350
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis.
Eusebi P; Giannandrea D; Biscetti L; Abraha I; Chiasserini D; Orso M; Calabresi P; Parnetti L
BMJ Open; 2016 Jun; 6(6):e011113. PubMed ID: 27297011
[TBL] [Abstract][Full Text] [Related]
4. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.
Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG
J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis.
Gao L; Tang H; Nie K; Wang L; Zhao J; Gan R; Huang J; Zhu R; Feng S; Duan Z; Zhang Y; Wang L
Int J Neurosci; 2015; 125(9):645-54. PubMed ID: 25202803
[TBL] [Abstract][Full Text] [Related]
6. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
7. Alpha-Synuclein as a Biomarker for Parkinson's Disease.
Atik A; Stewart T; Zhang J
Brain Pathol; 2016 May; 26(3):410-8. PubMed ID: 26940058
[TBL] [Abstract][Full Text] [Related]
8. Development of a Novel Electrochemiluminescence ELISA for Quantification of α-Synuclein Phosphorylated at Ser
Dutta S; Hornung S; Taha HB; Biggs K; Siddique I; Chamoun LM; Shahpasand-Kroner H; Lantz C; Herrera-Vaquero M; Stefanova N; Loo JA; Bitan G
ACS Chem Neurosci; 2023 Apr; 14(7):1238-1248. PubMed ID: 36920792
[TBL] [Abstract][Full Text] [Related]
9. Characterization of molecular biomarkers in cerebrospinal fluid and serum of E46K-SNCA mutation carriers.
Murueta-Goyena A; Cipriani R; Carmona-Abellán M; Acera M; Ayo N; Del Pino R; Tijero B; Fernández-Valle T; Gabilondo I; Zallo F; Matute C; Sánchez-Pernaute R; Khurana V; Cavaliere F; Capetillo-Zarate E; Gómez-Esteban JC
Parkinsonism Relat Disord; 2022 Mar; 96():29-35. PubMed ID: 35149357
[TBL] [Abstract][Full Text] [Related]
10. Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson's disease dementia, dementia with Lewy bodies and Alzheimer's disease.
Bougea A; Stefanis L; Paraskevas GP; Emmanouilidou E; Efthymiopoulou E; Vekrelis K; Kapaki E
J Neurol; 2018 Oct; 265(10):2295-2301. PubMed ID: 30083953
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O
Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206
[TBL] [Abstract][Full Text] [Related]
12. Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies.
Schmid AW; Fauvet B; Moniatte M; Lashuel HA
Mol Cell Proteomics; 2013 Dec; 12(12):3543-58. PubMed ID: 23966418
[TBL] [Abstract][Full Text] [Related]
13. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
[TBL] [Abstract][Full Text] [Related]
14. Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis.
Parnetti L; Cicognola C; Eusebi P; Chiasserini D
Biomark Med; 2016; 10(1):35-49. PubMed ID: 26643452
[TBL] [Abstract][Full Text] [Related]
15. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease.
El-Agnaf OM; Salem SA; Paleologou KE; Curran MD; Gibson MJ; Court JA; Schlossmacher MG; Allsop D
FASEB J; 2006 Mar; 20(3):419-25. PubMed ID: 16507759
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid and plasma distribution of anti-α-synuclein IgMs and IgGs in multiple system atrophy and Parkinson's disease.
Folke J; Rydbirk R; Løkkegaard A; Hejl AM; Winge K; Starhof C; Salvesen L; Pedersen LØ; Aznar S; Pakkenberg B; Brudek T
Parkinsonism Relat Disord; 2021 Jun; 87():98-104. PubMed ID: 34020303
[TBL] [Abstract][Full Text] [Related]
17. Quantification of Alpha-Synuclein in Biological Fluids by Electrochemiluminescence-Based Detection.
Kruse N; Mollenhauer B
Methods Mol Biol; 2019; 1948():59-68. PubMed ID: 30771170
[TBL] [Abstract][Full Text] [Related]
18. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease.
Majbour NK; Vaikath NN; van Dijk KD; Ardah MT; Varghese S; Vesterager LB; Montezinho LP; Poole S; Safieh-Garabedian B; Tokuda T; Teunissen CE; Berendse HW; van de Berg WD; El-Agnaf OM
Mol Neurodegener; 2016 Jan; 11():7. PubMed ID: 26782965
[TBL] [Abstract][Full Text] [Related]
19. Detection and Assessment of α-Synuclein Oligomers in the Urine of Parkinson's Disease Patients.
Nam D; Lee JY; Lee M; Kim J; Seol W; Son I; Ho DH
J Parkinsons Dis; 2020; 10(3):981-991. PubMed ID: 32444560
[TBL] [Abstract][Full Text] [Related]
20. Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies.
Stuendl A; Kunadt M; Kruse N; Bartels C; Moebius W; Danzer KM; Mollenhauer B; Schneider A
Brain; 2016 Feb; 139(Pt 2):481-94. PubMed ID: 26647156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
